Study wrapper · #596
Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats.
Editor's note
In streptozotocin-induced diabetic rats, researchers reported that impaired pulsatile growth-hormone (GH) secretion was accompanied by higher free fatty acids and lower IGF-1. Two weeks of hexarelin, a synthetic GH secretagogue, was associated with normalized pulsatile GH secretion and lower fasting free fatty acids, though it did not restore IGF-1, and it did not raise GH in non-diabetic controls. The nuance, that hexarelin corrected a deficient GH rhythm without pushing GH above normal, is the interesting part and fits the 'pulsatile' rationale for secretagogues. Limitations: a chemically induced diabetes model, short duration, and small numbers. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Researchers studied hexarelin, a lab-made peptide that stimulates growth hormone, in rats made diabetic with a chemical (streptozotocin). Diabetic rats had reduced natural pulsing of growth hormone, along with higher blood fatty acids and lower IGF-1 (a growth-related hormone). After two weeks of daily hexarelin injections, the diabetic rats' growth-hormone pulsing returned toward normal and their fasting fatty-acid levels dropped, though IGF-1 stayed low. Interestingly, hexarelin did not increase growth hormone in healthy control rats, suggesting it mainly corrected a deficiency rather than pushing hormone levels too high. The abstract reports no adverse events. These are preclinical findings in rats; human studies would be needed before any clinical conclusions.